Document is current

Article History

Received: 13 August 2025

Revised: 17 September 2025

Accepted: 7 November 2025

First Online: 5 December 2025

Competing interests

: Author SY: Advisory Board: Bristol Myers Squibb, Kite Pharma, Abbvie, Genmab; Consulting: Bristol Myers Squibb, Kite Pharma.

: All procedures were carried out in accordance with relevant institutional and federal ethical standards. Data for this analysis were obtained from the Center for International Blood and Marrow Transplant Research (CIBMTR), a research collaboration between the National Marrow Donor Program (NMDP) and the Medical College of Wisconsin. The CIBMTR is supported primarily by Public Health Service grant U24CA076518 from the National Cancer Institute, the National Heart, Lung, and Blood Institute, the National Institute of Allergy and Infectious Diseases, contract 75R60222C00011 from the Health Resources and Services Administration, and grants N00014-23-1-2057 and N00014-24-1-2057 from the Office of Naval Research. All CIBMTR studies are conducted in compliance with applicable federal regulations for the protection of human research participants. Written informed consent for data collection and research use was obtained from all participants. Institutional review boards of both the Medical College of Wisconsin and the National Marrow Donor Program approved the original CIBMTR study protocol.